Catalysts / CORT
Upcoming FDA decisions and readouts we track for Corcept Therapeutics, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Corcept Therapeutics (CORT, listed on Nasdaq). It concerns Relacorilant (Cushing's syndrome).
First on the list: the FDA decision expected for Relacorilant (Cushing's syndrome), dated 17 Dec 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 11 Sep 2026. The methodology page explains each status.
Background reading: What a PDUFA date is, and why the FDA doesn't publish them.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Corcept Therapeutics CORT · Nasdaq | Relacorilant | Cushing's syndrome | 17 Dec 2026 in 71d |
FDA decision expected | Verified | 8-K exhibit 99.1 ↗ | Yes |
FreeBioList